- Home
- INCY vs UMC Comparison
INCY vs UMC Comparison
Compare INCY & UMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- UMC
- Stock Information
- Founded
- INCY 1991
- UMC 1980
- Country
- INCY United States
- UMC Taiwan
- Employees
- INCY N/A
- UMC N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- UMC Semiconductors
- Sector
- INCY Health Care
- UMC Technology
- Exchange
- INCY Nasdaq
- UMC Nasdaq
- Market Cap
- INCY 14.2B
- UMC 14.5B
- IPO Year
- INCY 1993
- UMC 2000
- Fundamental
- Price
- INCY $75.23
- UMC $6.04
- Analyst Decision
- INCY Buy
- UMC Sell
- Analyst Count
- INCY 20
- UMC 4
- Target Price
- INCY $75.12
- UMC $7.40
- AVG Volume (30 Days)
- INCY 1.3M
- UMC 12.9M
- Earning Date
- INCY 02-10-2025
- UMC 01-21-2025
- Dividend Yield
- INCY N/A
- UMC 7.71%
- EPS Growth
- INCY N/A
- UMC N/A
- EPS
- INCY 0.15
- UMC 0.12
- Revenue
- INCY $4,075,860,000.00
- UMC $7,086,729,633.00
- Revenue This Year
- INCY $16.00
- UMC $9.89
- Revenue Next Year
- INCY $10.47
- UMC $12.26
- P/E Ratio
- INCY $499.49
- UMC $10.64
- Revenue Growth
- INCY 12.94
- UMC 4.39
- 52 Week Low
- INCY $50.35
- UMC $5.61
- 52 Week High
- INCY $83.95
- UMC $9.00
- Technical
- Relative Strength Index (RSI)
- INCY 59.31
- UMC 46.13
- Support Level
- INCY $72.60
- UMC $5.73
- Resistance Level
- INCY $75.18
- UMC $5.85
- Average True Range (ATR)
- INCY 1.72
- UMC 0.19
- MACD
- INCY 0.18
- UMC 0.02
- Stochastic Oscillator
- INCY 74.33
- UMC 51.85
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About UMC United Microelectronics Corporation (NEW)
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the US, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.